Please login to the form below

Not currently logged in
Email:
Password:

Dr George Gunn moves from Novartis to join Nuritas

The Irish biotech also adds to its advisory board

Nuritas Dr George GunnDublin-based biotech start-up Nuritas has appointed Dr George Gunn as chairman of its board of directors.

Dr Gunn joins from Novartis where he acted as head of the company's animal health division and as a member of its global executive committee from 2004 until early last year.

Prior to this, he also served as division head for consumer health and head of corporate social responsibility at Novartis, as well as occupying senior roles at Johnson & Johnson and Pharmacia.

Nuritas' chief executive officer Emmet Browne said: “George's depth of experience, knowledge and wisdom, gained at the highest levels of healthcare leadership, will be a huge addition to us as we deliver on the huge potential that lies within Nuritas.”

Meanwhile, Dr Dominique Bridon and Steve Morrison have been appointed to Nuritas' advisory board, adding expertise in strategic translational science, and food and product regulation respectively.

Dr Bridon has over 25 years of therapeutic discovery, translational research and formulation experience, which includes working in senior management roles at Ipsen and Pharmacia.

With over two decades of regulatory experience, Steve Morrison is currently the managing director of P2F and has previously served as chief operating officer for Provexis.

Founder and chief scientific officer of Nuritas Dr Nora Khaldi said: “From our first meetings it was clear that all three shared our passion for delivering life-changing ingredients.

“I am delighted that George, Dominique and Steve are joining us.”

26th January 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics